array:21 [
  "pii" => "X2013251414054562"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
  "estado" => "S300"
  "fechaPublicacion" => "2014-09-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2014;34:617-27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6687
    "formatos" => array:3 [
      "EPUB" => 330
      "HTML" => 5443
      "PDF" => 914
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514054565"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
      "estado" => "S300"
      "fechaPublicacion" => "2014-09-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:617-27"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 6781
        "formatos" => array:3 [
          "EPUB" => 305
          "HTML" => 5522
          "PDF" => 954
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Efectos del acetato cálcico/carbonato magnésico en el tratamiento de la hiperfosfatemia en pacientes en diálisis en la práctica clínica real. Seguimiento durante un año"
        "tienePdf" => "es"
        "tieneTextoCompleto" => 0
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "617"
            "paginaFinal" => "627"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Ángel L.M. de Francisco, Lara Belmar, Celestino Piñera, María Kislikova, Miguel Seras, Mara Serrano, Zoila Albines, Cristina Sango, Manuel Arias"
            "autores" => array:9 [
              0 => array:2 [
                "nombre" => "Ángel L.M."
                "apellidos" => "de Francisco"
              ]
              1 => array:2 [
                "nombre" => "Lara"
                "apellidos" => "Belmar"
              ]
              2 => array:2 [
                "nombre" => "Celestino"
                "apellidos" => "Piñera"
              ]
              3 => array:2 [
                "nombre" => "María"
                "apellidos" => "Kislikova"
              ]
              4 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "Seras"
              ]
              5 => array:2 [
                "nombre" => "Mara"
                "apellidos" => "Serrano"
              ]
              6 => array:2 [
                "nombre" => "Zoila"
                "apellidos" => "Albines"
              ]
              7 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Sango"
              ]
              8 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Arias"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414054562"
          "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054562?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054565?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000005/v0_201502091337/X0211699514054565/v0_201502091337/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414054554"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jul.11953"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:628-36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6252
      "formatos" => array:3 [
        "EPUB" => 337
        "HTML" => 5269
        "PDF" => 646
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Assessment of subclinical acute kidney injury after abdominal aortic aneurysm surgery using novel markers: L-FABP and H-FABP"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "628"
          "paginaFinal" => "636"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Evaluación de fracaso renal agudo subclínico tras cirugía de aneurisma aórtico abdominal utilizando nuevos marcadores: L-FABP y H-FABP"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11953_19904_58972_en_11953_t1.jpg"
              "Alto" => 781
              "Ancho" => 343
              "Tamanyo" => 410922
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Patients characteristics"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Michał Kokot, Grzegorz Biolik, Damian Ziaja, Tadeusz Fojt, Leszek Kędzierski, Katarzyna Antoniak, Mirosława Janowska, Krzysztof Pawlicki, Krzysztof Ziaja, Jan Duława"
          "autores" => array:10 [
            0 => array:2 [
              "nombre" => "Michał"
              "apellidos" => "Kokot"
            ]
            1 => array:2 [
              "nombre" => "Grzegorz"
              "apellidos" => "Biolik"
            ]
            2 => array:2 [
              "nombre" => "Damian"
              "apellidos" => "Ziaja"
            ]
            3 => array:2 [
              "nombre" => "Tadeusz"
              "apellidos" => "Fojt"
            ]
            4 => array:2 [
              "nombre" => "Leszek"
              "apellidos" => "Kędzierski"
            ]
            5 => array:2 [
              "nombre" => "Katarzyna"
              "apellidos" => "Antoniak"
            ]
            6 => array:2 [
              "nombre" => "Mirosława"
              "apellidos" => "Janowska"
            ]
            7 => array:2 [
              "nombre" => "Krzysztof"
              "apellidos" => "Pawlicki"
            ]
            8 => array:2 [
              "nombre" => "Krzysztof"
              "apellidos" => "Ziaja"
            ]
            9 => array:2 [
              "nombre" => "Jan"
              "apellidos" => "Duława"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054557"
        "doi" => "10.3265/Nefrologia.pre2014.Jul.11953"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054557?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054554?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054554/v0_201502091606/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414054570"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jun.12595"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2014;34:611-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5668
      "formatos" => array:3 [
        "EPUB" => 283
        "HTML" => 4677
        "PDF" => 708
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Home care programme for patients with advanced chronic kidney disease. A two-year experience"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "611"
          "paginaFinal" => "616"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Programa de atención domiciliaria a pacientes con enfermedad renal crónica avanzada. Experiencia de dos años"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier España"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12595_16025_61157_en_t112595.jpg"
              "Alto" => 944
              "Ancho" => 1059
              "Tamanyo" => 134152
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Baseline data at the time of inclusion in the programme"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "José L. Teruel, Lourdes Rexach, Víctor Burguera, Antonio Gomis, Nuria Rodríguez-Mendiola, Alicia Díaz, Sergio Collazo, Carlos Quereda"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "José L."
              "apellidos" => "Teruel"
            ]
            1 => array:2 [
              "nombre" => "Lourdes"
              "apellidos" => "Rexach"
            ]
            2 => array:2 [
              "nombre" => "Víctor"
              "apellidos" => "Burguera"
            ]
            3 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Gomis"
            ]
            4 => array:2 [
              "nombre" => "Nuria"
              "apellidos" => "Rodríguez-Mendiola"
            ]
            5 => array:2 [
              "nombre" => "Alicia"
              "apellidos" => "Díaz"
            ]
            6 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Collazo"
            ]
            7 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Quereda"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054573"
        "doi" => "10.3265/Nefrologia.pre2014.Jun.12595"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054573?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054570?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054570/v0_201502091605/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "617"
        "paginaFinal" => "627"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Ángel L.M. de Francisco, Lara Belmar, Celestino Piñera, María Kislikova, Miguel Seras, Mara Serrano, Zoila Albines, Cristina Sango, Manuel Arias"
        "autores" => array:9 [
          0 => array:4 [
            "nombre" => "Ángel L.M."
            "apellidos" => "de Francisco"
            "email" => array:1 [
              0 => "angelmartindefrancisco@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Lara"
            "apellidos" => "Belmar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Celestino"
            "apellidos" => "Pi&#241;era"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mar&#237;a"
            "apellidos" => "Kislikova"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Miguel"
            "apellidos" => "Seras"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Mara"
            "apellidos" => "Serrano"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Zoila"
            "apellidos" => "Albines"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Sango"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Arias"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria,  "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Efectos del acetato c&#225;lcico&#47;carbonato magn&#233;sico en el tratamiento de la hiperfosfatemia en pacientes en di&#225;lisis en la pr&#225;ctica cl&#237;nica real&#46; Seguimiento durante un a&#241;o"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60456_en_12527_t1.jpg"
            "Alto" => 472
            "Ancho" => 702
            "Tamanyo" => 235395
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patients and baseline characteristics"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">A number of US<span class="elsevierStyleSup">1</span> and European<span class="elsevierStyleSup">2</span> observational studies reported an increased mortality risk with hyperphosphataemia in dialysis patients&#46; Dietary restriction of phosphate and dialysis are usually not sufficient to control hyperphosphataemia&#46; Consequently&#44; oral phosphate binders are administered in the majority of dialysis patients&#46;</p><p class="elsevierStylePara">The ideal phosphate binder would avidly bind dietary phosphate&#44; have minimal systemic absorption&#44; few side effects&#44; a low pill burden and be inexpensive&#46; Calculations based on the doses usually applied indicated that the cost of treatment with sevelamer- or lanthanum-based agents is substantially higher than the cost of calcium- or magnesium-based binders&#46; Based on total sales figures&#44; annual costs of sevelamer or lanthanum exceeded those of calcium- or magnesium-based binders by four to eight times or more&#44; depending on the dose&#46;<span class="elsevierStyleSup">3</span></p><p class="elsevierStylePara">Calcium acetate&#47;magnesium carbonate &#40;CaMg&#41; is a combination phosphate binder&#46; Both components&#44; administered separately or together&#44; are already well-established phosphate-lowering agents&#46;<span class="elsevierStyleSup">4-14</span> As high doses of phosphate binders are often required to achieve sufficient phosphate reduction&#44; the risk of hypercalcaemia must be considered when using a pure calcium salt as a phosphate binder&#46; In calcium-magnesium combined preparations the proportion of calcium is reduced compared to drugs containing calcium salts only&#44; thus limiting the risk of hypercalcaemia and of a continuously positive calcium balance&#46;<span class="elsevierStyleSup">15</span> A controlled randomised trial investigated the effect of CaMg on serum phosphorus levels compared with sevelamer hydrochloride &#40;HCl&#41;&#46; CaMg was non-inferior to the comparator in controlling serum phosphorus levels at Week 25&#46; There was no change in ionised calcium&#59; there was minimal increase in total serum calcium and a small increase in serum magnesium&#46; CaMg had a good tolerability profile and thus may represent an effective treatment of hyperphosphataemia&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">However&#44; controlled clinical trials do not reflect the real world of clinical practice&#46; The use of less stringent inclusion&#47;exclusion criteria in observational studies allows a closer reflection of the overall patient population than in randomised clinical trials&#46;<span class="elsevierStyleSup">17</span> There is currently little information available on CaMg in real-life clinical practice&#46; The aim of this study was to investigate the use and effectiveness of CaMg in real-world clinical practice in patients on dialysis with hyperphosphataemia&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">SUBJECTS AND METHODS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study population</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Patients aged &#8805;18 years with chronic kidney disease &#40;CKD&#41; stage 5 on haemodialysis &#40;HD&#41; or peritoneal dialysis &#40;PD&#41; who had been prescribed CaMg to control serum phosphorus participated in this study&#46; The study was conducted in conformity with International Conference on Harmonisation - Good Clinical Practice &#40;ICH-GCP&#41; and the Declaration of Helsinki&#46; All patients provided their written informed consent prior to entering the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study design and procedure</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">This open-label&#44; prospective non-interventional observational study enrolled patients from a single centre &#40;Servicio de Nefrolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#44; Universidad de Cantabria&#44; Santander&#44; Spain&#41; between July 2010 and November 2013&#46; The treating physician exclusively determined initiation&#44; dose and duration of CaMg treatment based on recommendations outlined in department protocols&#46; Accordingly&#44; patients on phosphate binder treatment with inadequate phosphorus control or high pill burden or treatment-na&#239;ve patients with P &#62;5&#46;5mg&#47;dL &#40;1&#46;8mmol&#47;L&#41;&#44; Ca &#60;10&#46;4mg&#47;dL &#40;2&#46;6mmol&#47;L&#41;&#44; Mg &#60;3&#46;4mg&#47;dL &#40;1&#46;4mmol&#47;L&#41;&#44; parathyroid hormone &#40;PTH&#41; &#62;150pg&#47;mL &#40;16&#46;5pmol&#47;L&#41; and Kt&#47;V &#8805;1&#46;3 received CaMg &#40;calcium acetate 435mg containing 110mg elemental calcium combined with magnesium carbonate 235mg containing 60mg elemental magnesium &#91;OsvaRen<span class="elsevierStyleSup">&#174;</span>&#93;&#41; at doses determined by the treating physician&#46; Patients received an initial dose prescribed by physicians related to serum phosphorus levels but in general 3-4 pills&#47;day&#46; Dose increase or decrease was based on serum phosphorus levels&#46; Co-medication was maintained according to patient requirements&#46; No clinic visits were required other than those regularly scheduled&#46; No laboratory or diagnostic tests were performed other than those associated with usual patient care&#46; Routine biochemical parameters were measured using standard methods&#46; Measurement of intact PTH was performed using the Scantibodies Total Intact PTH &#40;Abraham Way&#44; Santee&#44; CA 92071&#41;&#46;</p><p class="elsevierStylePara">Besides patient demographics PTH&#44; serum phosphorus&#44; calcium&#44; magnesium and albumin concentration was obtained at baseline and after 3&#44; 6 and 12 months of CaMg treatment respectively&#46; CaMg dosage&#44; concurrent phosphate binder usage&#44; vitamin D and cinacalcet usage were documented throughout the study&#46; Tolerability was assessed by means of adverse event profile and safety laboratory parameters at each study visit&#46;</p><p class="elsevierStylePara">The primary endpoint of this study was efficacy of CaMg in real clinical practice&#44; measured as change in serum phosphorus over one year&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analysis</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">All data analyses were carried out according to a pre-established analysis plan&#46; The collected data were analysed with epidemiological methods&#44; using the SPSS for Windows programme package &#40;Version 15&#46;0&#44; Chicago&#44; IL&#41;&#46; For continuous variables&#44; statistic parameters including arithmetic mean&#44; standard deviation and range were calculated&#46; Frequency distributions for discrete variables were provided as percentage in relation to the total sample&#46; Evaluation of parameters measuring the clinical course was performed by intraindividual difference analysis using the Student&#8217;s t-test&#46; Differences were calculated per patient and subsequently averaged&#46; For normality and homogeneity of data&#44; Kolgomorov-Smirnow and Levene tests were used&#46; For comparison between groups&#44; the T-Test and Mann-Whitney U test was applied&#46; Missing data were not imputed&#46; All tests were two-sided&#44; and significance was declared at the 0&#46;05 level&#46; Corrected calcium &#40;mg&#47;dL&#41; was calculated as total calcium &#40;mg&#47;dL&#41; &#43; 0&#46;8 &#91;4&#46;0 &#8211; albumin &#40;g&#47;dL&#41;&#93;&#46; For analysis&#44; patients were divided post-hoc into 2 subgroups&#46; Group A comprised patients receiving CaMg alone&#44; group B comprised patients receiving CaMg in addition to one or more other phosphate binders&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patients and baseline characteristics</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In total&#44; 120 patients participated in the study&#46; At database lock&#44; one-year data were available from 67 patients &#40;Figure 1&#41;&#46; Patient demographics&#44; magnesium concentration in dialysis fluids&#44; and baseline laboratory values at initiation of CaMg therapy are shown in Table 1&#46; Ninety-five patients received haemodialysis &#40;61 conventional haemodialysis and 34 on-line hemodiafiltration&#41;&#44; 25 patients were on peritoneal dialysis&#46; Magnesium concentration in the dialysis fluid was 0&#46;5mmol&#47;L &#40;1&#46;2mg&#47;dL&#41; with the exception of 5 PD patients for whom a dialysis solution containing 0&#46;25mmol&#47;L &#40;0&#46;6mg&#47;dL&#41; &#40;Baxter<span class="elsevierStyleSup">&#174;</span>&#41; was used&#46; 79 out of 120 patients received CaMg alone and 41 patients CaMg plus concurrent phosphate binder&#46; In addition to phosphate binding agents&#44; patients received calcitriol&#44; paricalcitol and calcimimetics &#40;Table 2&#41;&#46; At baseline&#44; calcium carbonate and lanthanum carbonate were administered most frequently &#40;23&#37; and 28&#37;&#44; respectively&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Phosphate binder dosage</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Once CaMg was introduced&#44; phosphate binders remained either unchanged&#44; or were reduced or stopped during the observation period&#46; No dose increases were observed during the course of the study&#44; nor were new phosphate binding agents initiated&#46; Before introducing CaMg&#44; there was no washout period considered in clinical practice&#46; At the end of month 12&#44; mean &#40;&#177;SD&#41; pill number of CaMg was 4&#46;75&#177;1&#46;50&#46; In the group CaMg alone &#40;n&#58;41&#41;&#44; at the end of the month 12&#44; mean &#40;&#177;SD&#41; pill number of CaMg was 4&#46;48&#177;1&#46;66&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleBold">Evolution of serum phosphorus levels over time</span></span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Significant reductions in serum phosphorus were achieved in both treatment groups &#40;Figure 2&#41;&#46; No differences were observed between the groups as to the degree of phosphate decrease&#46; Serum phosphorus levels were similar between the groups at all time-points&#46; At baseline&#44; the majority of patients had serum phosphorus levels above the Kidney Disease Improving Global Outcome &#40;KDIGO&#41; and Kidney Disease Outcomes Quality Initiative &#40;K&#47;DOQI&#41; recommended target of 4&#46;5mg&#47;dL &#40;1&#46;4mmol&#47;L&#41; and 5&#46;5mg&#47;dL &#40;1&#46;8mmol&#47;L&#41; respectively&#46; During the course of the study the number of patients with phosphorus levels within the target range increased in both groups &#40;Figure 3&#41;&#46; The highest number of patients within the K&#47;DOQI target range was achieved at 6 months with 78&#37; of patients combined from both groups and at one year with 75&#37;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolucition of calcium over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">After initiation of CaMg&#44; corrected calcium increased in both groups similarly &#40;Figure 4&#41;&#46; In the group receiving CaMg alone&#44; increases were significant compared to baseline at all time-points&#44; whereby in the group receiving CaMg in combination with other phosphate binders&#44; the differences versus baseline reached statistical significance at month 6&#46; Only three out of 120 patients had transient Ca levels mildly above the upper limit of normal &#40;&#62;10&#46;4mg&#47;dL&#44; &#62;2&#46;6mmol&#47;L&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolucition of magnesium over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In patients receiving CaMg alone&#44; magnesium levels increased significantly from 2&#46;44&#177;0&#46;45mg&#47;dL &#40;1&#46;00&#177;0&#46;19mmol&#47;L&#41; at baseline to 2&#46;75&#177;0&#46;44mg&#47;dL &#40;1&#46;13&#177;0&#46;18mmol&#47;L&#41; at the end of one year treatment &#40;p&#60;0&#46;001&#41;&#46; No significant increases were observed in the group receiving combination treatment &#40;Figure 5&#41;&#46; In this group&#44; baseline levels were significantly higher compared to the monotherapeutic group &#40;2&#46;61&#177;0&#46;44mg&#47;dL vs&#46; 2&#46;35&#177;0&#46;43mg&#47;dL &#47; 1&#46;07&#177;0&#46;18mmol&#47;L vs&#46; 0&#46;97&#177;0&#46;18mmol&#47;L&#41;&#46; Magnesium levels were similar in both groups during months 3 to 12&#46; A total of 80 patients &#40;67&#37;&#41; experienced episodes of mild hypermagnesaemia &#40;&#62;2&#46;6mg&#47;mL&#44; 1&#46;05mmol&#47;L&#41; during CaMg treatment&#46; No cases of moderate hypermagnesaemia &#40;4&#46;8-8&#46;6mg&#47;dL&#44; 2&#46;0-3&#46;6mmol&#47;L&#41; were observed&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolution of PTH over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">PTH decreased in both groups over time &#40;Figure 6&#41;&#44; whereby PTH levels were generally lower at all time-points in the group receiving monotherapy&#46; Here&#44; decreases from baseline were significant at all time-points&#46; In the group receiving CaMg in addition to other phosphate binders&#44; the decrease was less pronounced&#44; reaching significance only at month 6&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolution of albumin over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Albumin levels increased slightly throughout the study &#40;Figure 7&#41;&#46; In monotherapy group the increase from baseline was statistically significant only in month 6&#46; From month 3 on&#44; albumin levels were significantly higher in the group receiving CaMg in addition to another phosphate binder&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Safety</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In total&#44; 53 patients &#40;44&#46;2&#37;&#41; discontinued CaMg due to transplantation &#40;34&#37;&#41;&#44; exitus &#40;11&#46;3&#37;&#41;&#44; Transfer to another hospital &#40;1&#46;9&#37;&#41;&#44; treatment completion &#40;50&#46;9&#37;&#41; and no analytical data &#40;1&#46;9&#37;&#41;&#46; No treatment-related serious adverse events were reported during the course of the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The present observational study explored the effect of CaMg on serum phosphorus levels over one year in dialysis patients under real practice conditions&#46; CaMg treatment resulted in statistically significant reductions in serum phosphorus without affecting the control of related laboratory parameters such as magnesium&#44; calcium&#44; PTH and albumin&#46; This effectiveness of CaMg in clinical practice is consistent with results observed in a randomised controlled clinical trial&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">The publication of K&#47;DOQI clinical guidelines for Bone Metabolism and Disease in 2003<span class="elsevierStyleSup">18</span> promoted significant progress in the issues related to mineral metabolism in CKD&#46; Motivated by the growing evidence regarding the association of mineral metabolism disturbances and cardiovascular disease in CKD&#44; the KDIGO workgroup recommended new targets for mineral metabolism related biochemical parameters&#46;<span class="elsevierStyleSup">19</span> However&#44; several observational studies have concluded that compliance with mineral metabolism targets in dialysis patients was poor&#46; Al Aly et al&#46; reported that CKD-MBD biochemical markers in the majority of dialysis patients fell outside K&#47;DOQI targets&#44; with only 40&#37; having serum phosphorus within the recommended ranges&#46;<span class="elsevierStyleSup">20</span> We have also previously shown in 1&#44;312 patients undergoing haemodialysis at six Spanish centers that the prevalence of patients outside of K&#47;DOQI targets for phosphorus was 46&#37;&#46;<span class="elsevierStyleSup">21</span> Serum phosphate levels are not controlled in &#62;50&#37; of HD patients&#44; mainly because the effectiveness of any phosphate binder therapy is compromised by poor adherence due to high pill burden&#46; At the end of one year of CaMg treatment&#44; the mean number of tablets required to achieve phosphorus control was 4&#46;75&#177;1&#46;50&#44; which is lower than the number of CaMg tablets administered in the CALMAG study &#40;7&#46;3&#177;3&#46;03 tablets per day&#41;&#46;<span class="elsevierStyleSup">16</span> Higher numbers of tablets have been reported in other studies using calcium salts&#46;<span class="elsevierStyleSup">5&#44;6&#44;8</span> This reduction of pill burden might translate into better compliance which&#44; in turn&#44; leads to improved outcomes&#46; Accordingly&#44; in the present study&#44; 78&#37; of patients achieved the K&#47;DOQI target range for serum phosphorus at the end of 6 months treatment with CaMg&#46;</p><p class="elsevierStylePara">Phosphate binders have been used for many years&#44; but the ideal binder in terms of efficacy&#44; patient adherence&#44; safety and costs has yet to be found&#46; Phosphate binders containing aluminium or calcium have well-known drawbacks&#44; such as aluminium toxicity or increased calcium load causing hypercalcaemia which has been associated with vascular calcification&#46; Newer agents such as sevelamer- and lanthanum-based binders avoid calcium burden but are very expensive&#46; Magnesium-containing phosphate binders offer a chance to circumvent some of the problems associated with other agents&#46; In spite of good experience with the use of magnesium-based phosphate binders and excellent results&#44;<span class="elsevierStyleSup">9-14</span> the impact of magnesium in CKD patients still remains unclear in clinical routine practice&#46; The CALMAG study compared safety parameters of CaMg to sevelamer hydrochloride&#46;<span class="elsevierStyleSup">16</span> Both regimens were equally well tolerated with a similar number of adverse events&#46;</p><p class="elsevierStylePara">In our study we observed mild increases in serum magnesium from baseline at the end of one year treatment&#44; but no symptomatic hypermagnesaemia was observed&#46; Although a small increase in serum magnesium occurred in the CaMg group in the CALMAG study&#44; the mean concentration was consistently well below potential symptomatic levels &#40;&#60;4&#46;8mg&#47;dL &#47; 2&#46;0mmol&#47;L&#41;&#46; In fact&#44; this minor increase in serum magnesium may have beneficial effects&#46; Various epidemiological studies demonstrated associations between low serum magnesium levels and an increased risk for metabolic syndrome&#44; type 2 diabetes mellitus &#40;T2DM&#41;&#44; hypertension and atherosclerosis&#46;<span class="elsevierStyleSup">22</span> However&#44; the use of magnesium as a therapeutic agent is only indicated for pre-eclampsia and specific forms of arrhythmias&#46; In a recent study by Khan et al&#46; evaluating 3&#44;530 participants&#44; multivariable-adjusted models indicated that individuals in the lowest quartile of serum magnesium were ~50&#37; more likely to develop atrial fibrillation&#46;<span class="elsevierStyleSup">23</span> In this context&#44; it is important to consider data from a recent meta-analysis reporting an 11&#46;6&#37; prevalence of atrial fibrillation in dialysis patients&#46; The overall incidence of 2&#46;7&#47;100 patient-years was higher than in the general population and has been associated with an increased risk of stroke and mortality&#46;<span class="elsevierStyleSup">24</span> Moreover&#44; magnesium supplementation and mild hypermagnesaemia might have beneficial effects in CKD patients with regards to calcification and mortality&#46;<span class="elsevierStyleSup">25</span> There is concern that increased serum magnesium levels may affect bone in dialysis patients dependent as well as independent of its PTH-lowering effect&#46;<span class="elsevierStyleSup">26</span> In this context&#44; we need more information about the bone effects of magnesium but preliminary data obtained from the CALMAG study shows that CaMg and sevelamer-HCl lower serum levels of iFGF-23 to a similar extent&#46; Changes in bone parameters were dependent on characteristics of the respective phosphate binder&#59; in contrast to sevelamer-HCl&#44; CaMg had no impact on bone turnover markers&#46; In fact the bone turnover parameters alkaline phosphatase&#44; bone AP&#44; procollagen type 1 amino-terminal propeptide 1 osteoprotegerin&#44; beta-crosslaps and tartrate-resistant acid phosphatase 5b increased significantly in the sevelamer-HCl group and they remained almost unchanged in the CaMg group&#44; after the initial phase of P lowering&#46;<span class="elsevierStyleSup">27</span> Further studies would be needed that could give us information about the long-term effects of elevated levels of serum magnesium in patients on dialysis&#46;</p><p class="elsevierStylePara">In our study&#44; a dialysis magnesium concentration of 1&#46;2mg&#47;dL &#40;0&#46;5mmol&#47;L&#41; was used in more than 95&#37; of patients&#46; In dialysis patients&#44; magnesium concentrations are dependent mainly on dialysate magnesium&#46; Magnesium crosses the dialysis and peritoneal membrane readily&#46; Investigation of various magnesium dialysate concentrations in patients undergoing haemodialysis or peritoneal dialysis showed that concentrations of 1&#46;8mg&#47;dL &#40;0&#46;75mmol&#47;L&#41; may cause mild hypermagnesaemia&#44; whereas a concentration of 0&#46;6mg&#47;dL &#40;0&#46;25mmol&#47;L&#41; often leads to hypomagnesaemia&#46; Results for the magnesium dialysate concentration of 1&#46;2mg&#47;dL &#40;0&#46;5mmol&#47;L&#41; are less consistent but magnesium levels were within the normal range in the majority of cases&#46;<span class="elsevierStyleSup">28</span> The inconsistent results of several studies suggest that other factors&#44; such as nutrition and magnesium supplements &#40;e&#46;g&#46; antacids&#41;&#44; may also play an important role in determining serum magnesium levels in dialysis patients&#46;</p><p class="elsevierStylePara">Finally&#44; magnesium containing phosphate binders are relatively inexpensive compared to sevelamer- or lanthanum-based agents&#46; Calculated costs for the treatment with CaMg were about 80&#37; lower compared to sevelamer hydrochloride&#46;<span class="elsevierStyleSup">16&#44;29</span> Nephrologists raised some concerns about the costs of introducing magnesium monitoring&#46; That&#44; however&#44; would be offset by the lower cost of magnesium-containing phosphate binders over sevelamer or lanthanum&#46; Furthermore&#44; most modern multi-channel biochemistry analysers include the measurement of magnesium&#44; if required&#44; without major cost implications&#46;<span class="elsevierStyleSup">30</span></p><p class="elsevierStylePara">A recent metanalisis included all randomised and non-randomised trials that compared outcomes between patients with chronic kidney disease taking calcium-based phosphate binders &#40;with those taking non-calcium-based binders&#46; The final interpretation is that non-calcium-based phosphate binders are associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease&#46;<span class="elsevierStyleSup">31</span> In our opinion further studies are needed comparing Ca-Mg binders &#40;with low amount of calcium and magnesium effect&#41; with non calcium binders</p><p class="elsevierStylePara">Potential limitations of this study are possible bias introduced by the real world of clinical practice&#46; Physicians prescribe drugs based on their own decisions and the study does not include a washout period before starting CaMg treatment as in controlled clinical trials&#46; The results from this study would have been strengthened if an active comparator or placebo arm had been included&#46; But the present study was designed to assess whether results obtained from clinical trials of CaMg could be replicated in the clinical practice setting&#46; Additional limitations include that dietary data were not collected in this study&#44; primarily for the purpose of ensuring consistency of dietary phosphate intake&#46; We did not precisely record tolerability&#44; but efficacy and tolerability of CaMg have been well documented in previous studies&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">In order to determine the effect of co-medication on phosphorus control by CaMg&#44; conduction of a multivariable analysis was intended&#46; However&#44; this approach was not feasible due to the non-interventional nature of this study&#46; Subgroups with distinct allocation of calcium-containing and calcium-free phosphate binders were too small to yield significant results&#46; Controlled&#44; randomised clinical trials are required to explore the impact of co-medication on phosphorus control&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSIONS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Magnesium-containing phosphate binders have certain intrinsic advantages&#44; since their use avoids aluminium toxicity and allows calcium intake to be reduced or eliminated&#46; The combination of calcium acetate and magnesium carbonate presents a phosphate binder&#44; which is effective and well tolerated in clinical practice&#44; and saves about 80&#37; of treatment costs&#46; Magnesium levels were only slightly elevated and there was minimal increase in total serum calcium&#46; This analysis of current clinical practice shows that &#8211;consistent with findings from a randomised controlled trial&#8211; CaMg treatment provides marked improvement in serum levels of phosphorus helping patients in trying to achieve K&#47;DOQI and KDIGO targets&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Authors declare potential Conflicts of Interest&#46;</p><p class="elsevierStylePara">Honorarios por ponencias&#58; Amgen&#44; Fresenius&#44; Genzyme and Shire&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60456&#95;en&#95;12527&#95;t1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60456_en_12527_t1.jpg" alt="Patients and baseline characteristics"></img></a></p><p class="elsevierStylePara">Table 1&#46; Patients and baseline characteristics</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60457&#95;en&#95;12527&#95;t2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60457_en_12527_t2.jpg" alt="Concomitant medication at baseline"></img></a></p><p class="elsevierStylePara">Table 2&#46; Concomitant medication at baseline</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60458&#95;en&#95;12527&#95;f1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60458_en_12527_f1.jpg" alt="Diagram describing the patient flow"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Diagram describing the patient flow</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60459&#95;en&#95;12527&#95;f2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60459_en_12527_f2.jpg" alt="Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD"></img></a></p><p class="elsevierStylePara">Figure 2&#46; Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60460&#95;en&#95;12527&#95;f3&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60460_en_12527_f3.jpg" alt="Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time"></img></a></p><p class="elsevierStylePara">Figure 3&#46; Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60461&#95;en&#95;12527&#95;f4&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60461_en_12527_f4.jpg" alt="Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 4&#46; Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD </p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60462&#95;en&#95;12527&#95;f5&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60462_en_12527_f5.jpg" alt="Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD"></img></a></p><p class="elsevierStylePara">Figure 5&#46; Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60463&#95;en&#95;12527&#95;f6&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60463_en_12527_f6.jpg" alt="Evolution of PTH over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 6&#46; Evolution of PTH over time&#46; Data are presented as means&#177;SD </p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60464&#95;en&#95;12527&#95;f7&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60464_en_12527_f7.jpg" alt="Evolution of albumin over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 7&#46; Evolution of albumin over time&#46; Data are presented as means&#177;SD </p>"
    "pdfFichero" => "P1-E574-S4691-A12527-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437447"
          "palabras" => array:1 [
            0 => "Acetato c&#225;lcico&#47;carbonato magn&#233;sico"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437449"
          "palabras" => array:1 [
            0 => "Hiperfosfatemia"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437451"
          "palabras" => array:1 [
            0 => "Di&#225;lisis"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437453"
          "palabras" => array:1 [
            0 => "Quelante de f&#243;sforo"
          ]
        ]
      ]
      "en" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437448"
          "palabras" => array:1 [
            0 => "Calcium acetate&#47;magnesium carbonate"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437450"
          "palabras" => array:1 [
            0 => "Hyperphosphataemia"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437452"
          "palabras" => array:1 [
            0 => "Dialysis"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437454"
          "palabras" => array:1 [
            0 => "Phosphate binder"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Antecedentes&#58;</span> Este estudio observacional se llev&#243; a cabo para investigar el uso y la efectividad&#44; en la pr&#225;ctica cl&#237;nica real&#44; del acetato c&#225;lcico&#47;carbonato magn&#233;sico &#40;CaMg&#41; en el tratamiento de la hiperfosfatemia en pacientes en di&#225;lisis&#46;<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">M&#233;todos&#58;</span> Se realiz&#243; un seguimiento durante 3-12&#160;meses en 120&#160;pacientes adultos con enfermedad cr&#243;nica renal en tratamiento con di&#225;lisis que recib&#237;an monotratamiento con CaMg o en combinaci&#243;n con otros quelantes del f&#243;sforo&#46; Se midieron en suero los valores de f&#243;sforo&#44; calcio&#44; magnesio&#44; hormona paratiroidea y concentraci&#243;n de alb&#250;mina a nivel basal y tras 3&#44; 6 y 12&#160;meses&#44; respectivamente&#46; Adem&#225;s&#44; se document&#243; la dosis de CaMg&#44; el uso de quelantes de f&#243;sforo concomitantes&#44; la vitamina D y el cinacalcet&#46; Los pacientes se dividieron en 2&#160;subgrupos&#58; aquellos a los que solo se les administraba CaMg &#40;n&#61;79&#41; frente a los que recib&#237;an CaMg y un quelante de f&#243;sforo concomitante &#40;n&#61;41&#41;&#46; <span class="elsevierStyleBold">Resultados&#58;</span> En ambos subgrupos&#44; los niveles de f&#243;sforo s&#233;rico disminuyeron de forma significativa&#44; con respecto a los basales&#44; a los 3&#44; 6 y 12 meses de tratamiento con CaMg&#46; El porcentaje de logro de los niveles recomendados de f&#243;sforo s&#233;rico mejor&#243; tras iniciar el tratamiento con CaMg&#46; El mes&#160;6&#44; un total del 78&#37; se encontraba dentro de las recomendaciones objetivo de Calidad de los Resultados de la Insuficiencia Renal &#40;K&#47;DOQI&#41;&#46; El calcio s&#233;rico total corregido aument&#243; durante el tratamiento con CaMg&#44; pero superaba levemente los l&#237;mites superiores normales solo en tres pacientes&#46; Asimismo&#44; se observaron incrementos significativos del magnesio asintom&#225;ticos &#40;<span class="elsevierStyleItalic">P</span>&#60;0&#44;001&#41; en el grupo de monoterapia a los 3&#44; 6 y 12&#160;meses&#46; Un total de 80&#160;pacientes &#40;67&#37;&#41; sufrieron episodios de hipermagnesemia leve &#40;&#62;2&#44;6&#160;mg&#47;mL&#44; 1&#44;05&#160;mmol&#47;L&#41;&#46;<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">Conclusiones&#58;</span><span class="elsevierStyleBold"> </span>El presente an&#225;lisis de la pr&#225;ctica cl&#237;nica habitual&#44; en consonancia con los datos obtenidos de un ensayo aleatorizado controlado&#44; demuestra que el tratamiento con CaMg mejora de forma considerable los niveles de f&#243;sforo s&#233;rico y ayuda a los pacientes a conseguir los objetivos K&#47;DOQI y KDIGO &#40;mejora de los resultados globales en la enfermedad renal&#41;&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Background&#58; </span>This observational study was conducted to investigate the use and effectiveness of calcium acetate&#47;magnesium carbonate &#40;CaMg&#41; in the treatment of hyperphosphataemia in dialysis patients in real-world clinical practice&#46; <span class="elsevierStyleBold">Methods&#58; </span>120 adult CKD patients on dialysis who received CaMg alone or in combination with other phosphate binders were followed-up for 3-12 months&#46; Serum phosphorus&#44; calcium&#44; magnesium&#44; parathyroid hormone and albumin concentration was measured at baseline and after 3&#44; 6 and 12 months respectively&#46; In addition&#44; CaMg dosage&#44; use of concurrent phosphate binders&#44; vitamin D and cinacalcet was documented&#46; Patients were evaluated in 2 subgroups &#8211; CaMg alone &#40;n&#61;79&#41; vs&#46; CaMg &#43; concurrent phosphate binder &#40;n&#61;41&#41;&#46; <span class="elsevierStyleBold">Results&#58; </span>In both subgroups serum phosphorus levels decreased significantly from baseline at 3&#44; 6 and 12 months of CaMg treatment&#46; The percentage achievement of recommended serum phosphorus targets improved after CaMg initiation&#46; At month 6&#44; a total of 78&#37; were within the Kidney Disease Outcomes Quality Initiative &#40;K&#47;DOQI&#41; target range&#46; Total corrected serum calcium increased during CaMg treatment&#44; but mildly exceeded the upper limit of normal in three patients only&#46; Asymptomatic significant increases in magnesium &#40;p&#60;0&#46;001&#41; were observed in the monotherapy group at 3&#44; 6 and 12 months&#46; A total of 80 patients &#40;67&#37;&#41; experienced episodes of mild hypermagnesaemia &#40;&#62;2&#46;6mg&#47;mL&#44; 1&#46;05mmol&#47;L&#41;&#46;<span class="elsevierStyleBold"> Conclusions&#58; </span>This analysis of current clinical practice shows that &#8211; consistent with findings from a randomised controlled trial &#8211; CaMg treatment leads to marked improvement in serum phosphorus levels&#44; helping patients in trying to achieve K&#47;DOQI and KDIGO &#40;Kidney Disease Improving Global Outcome&#41; targets&#46;</p>"
      ]
    ]
    "multimedia" => array:9 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60456_en_12527_t1.jpg"
            "Alto" => 472
            "Ancho" => 702
            "Tamanyo" => 235395
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patients and baseline characteristics"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60457_en_12527_t2.jpg"
            "Alto" => 270
            "Ancho" => 420
            "Tamanyo" => 121478
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Concomitant medication at baseline"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60458_en_12527_f1.jpg"
            "Alto" => 637
            "Ancho" => 422
            "Tamanyo" => 217587
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Diagram describing the patient flow"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60459_en_12527_f2.jpg"
            "Alto" => 371
            "Ancho" => 700
            "Tamanyo" => 167556
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60460_en_12527_f3.jpg"
            "Alto" => 473
            "Ancho" => 700
            "Tamanyo" => 166417
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60461_en_12527_f4.jpg"
            "Alto" => 378
            "Ancho" => 698
            "Tamanyo" => 168462
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      6 => array:8 [
        "identificador" => "fig7"
        "etiqueta" => "Fig. 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60462_en_12527_f5.jpg"
            "Alto" => 396
            "Ancho" => 700
            "Tamanyo" => 165645
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      7 => array:8 [
        "identificador" => "fig8"
        "etiqueta" => "Fig. 6"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60463_en_12527_f6.jpg"
            "Alto" => 378
            "Ancho" => 700
            "Tamanyo" => 168646
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of PTH over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      8 => array:8 [
        "identificador" => "fig9"
        "etiqueta" => "Fig. 7"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60464_en_12527_f7.jpg"
            "Alto" => 380
            "Ancho" => 700
            "Tamanyo" => 160166
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of albumin over time&#46; Data are presented as means&#177;SD"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:31 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9531176" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-55. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20466670" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362(14):1312-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20375408" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 2006;1:704-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699276" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086935" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Qunibi WY, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18423809" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrol Dial Transplant 1993;8:341-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8390009" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991;6:170-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1866045" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Delmez JA, Tindira CA, Windus DW, Norwood KY, Giles KS, Nighswander TL, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1391713" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996;49:163-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8770963" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 2007;17:416-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17971314" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial 2007;20:333-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17635824" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009;13:453-59."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40:193-201. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18193489" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Deuber HJ. Long-term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. Nieren-und Hochdruckkrankheiten 2004;33:403-8."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20530499" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrol Dial Transplant 2009;24(9):2852-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19369690" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-S202."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int \u{A0}Suppl 2009;(113):S1-S130."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004;24:422-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15308874" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006;21(2):459-65."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Geiger H, Wanner C. Magnesium in disease. Clin Kidney J 2012;5(Suppl 1):i25-i38."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013;127(1):33-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23172839" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27(10):3816-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23114904" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012;5(Suppl 1):i52-i61."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009;22:37-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19250445" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28(9):2383-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23787550" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012;5(Suppl 1):i39-i51."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ Rev 2011;1(1):1. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22828213" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "De Francisco ALM, Rodriguez M. Magnesium ¿ its role in CKD. Nefrologia 2013;33(3):389-99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23640095" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23870817" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054562/v0_201502091605/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000005/v0_201502091605/X2013251414054562/v0_201502091605/en/P1-E574-S4691-A12527-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054562?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Effect of calcium acetate/magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice. One year follow up
Efectos del acetato cálcico/carbonato magnésico en el tratamiento de la hiperfosfatemia en pacientes en diálisis en la práctica clínica real. Seguimiento durante un año
Ángel L.M. de Franciscoa, Lara Belmara, Celestino Piñeraa, María Kislikovaa, Miguel Serasa, Mara Serranoa, Zoila Albinesa, Cristina Sangoa, Manuel Ariasa
a Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria,
Read
12100
Times
was read the article
2777
Total PDF
9323
Total HTML
Share statistics
 array:21 [
  "pii" => "X2013251414054562"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
  "estado" => "S300"
  "fechaPublicacion" => "2014-09-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:617-27"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 6687
    "formatos" => array:3 [
      "EPUB" => 330
      "HTML" => 5443
      "PDF" => 914
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699514054565"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
      "estado" => "S300"
      "fechaPublicacion" => "2014-09-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2014;34:617-27"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 6781
        "formatos" => array:3 [
          "EPUB" => 305
          "HTML" => 5522
          "PDF" => 954
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Efectos del acetato c&#225;lcico&#47;carbonato magn&#233;sico en el tratamiento de la hiperfosfatemia en pacientes en di&#225;lisis en la pr&#225;ctica cl&#237;nica real&#46; Seguimiento durante un a&#241;o"
        "tienePdf" => "es"
        "tieneTextoCompleto" => 0
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "617"
            "paginaFinal" => "627"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Effect of calcium acetate&#47;magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice&#46; One year follow up"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "&#193;ngel L&#46;M&#46; de Francisco, Lara Belmar, Celestino Pi&#241;era, Mar&#237;a Kislikova, Miguel Seras, Mara Serrano, Zoila Albines, Cristina Sango, Manuel Arias"
            "autores" => array:9 [
              0 => array:2 [
                "nombre" => "&#193;ngel L&#46;M&#46;"
                "apellidos" => "de Francisco"
              ]
              1 => array:2 [
                "nombre" => "Lara"
                "apellidos" => "Belmar"
              ]
              2 => array:2 [
                "nombre" => "Celestino"
                "apellidos" => "Pi&#241;era"
              ]
              3 => array:2 [
                "nombre" => "Mar&#237;a"
                "apellidos" => "Kislikova"
              ]
              4 => array:2 [
                "nombre" => "Miguel"
                "apellidos" => "Seras"
              ]
              5 => array:2 [
                "nombre" => "Mara"
                "apellidos" => "Serrano"
              ]
              6 => array:2 [
                "nombre" => "Zoila"
                "apellidos" => "Albines"
              ]
              7 => array:2 [
                "nombre" => "Cristina"
                "apellidos" => "Sango"
              ]
              8 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Arias"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251414054562"
          "doi" => "10.3265/Nefrologia.pre2014.Jul.12527"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054562?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054565?idApp=UINPBA000064"
      "url" => "/02116995/0000003400000005/v0_201502091337/X0211699514054565/v0_201502091337/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251414054554"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jul.11953"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:628-36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6252
      "formatos" => array:3 [
        "EPUB" => 337
        "HTML" => 5269
        "PDF" => 646
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Assessment of subclinical acute kidney injury after abdominal aortic aneurysm surgery using novel markers&#58; L-FABP and H-FABP"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "628"
          "paginaFinal" => "636"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Evaluaci&#243;n de fracaso renal agudo subcl&#237;nico tras cirug&#237;a de aneurisma a&#243;rtico abdominal utilizando nuevos marcadores&#58; L-FABP y H-FABP"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11953_19904_58972_en_11953_t1.jpg"
              "Alto" => 781
              "Ancho" => 343
              "Tamanyo" => 410922
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Patients characteristics"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Micha&#322; Kokot, Grzegorz Biolik, Damian Ziaja, Tadeusz Fojt, Leszek K&#281;dzierski, Katarzyna Antoniak, Miros&#322;awa Janowska, Krzysztof Pawlicki, Krzysztof Ziaja, Jan Du&#322;awa"
          "autores" => array:10 [
            0 => array:2 [
              "nombre" => "Micha&#322;"
              "apellidos" => "Kokot"
            ]
            1 => array:2 [
              "nombre" => "Grzegorz"
              "apellidos" => "Biolik"
            ]
            2 => array:2 [
              "nombre" => "Damian"
              "apellidos" => "Ziaja"
            ]
            3 => array:2 [
              "nombre" => "Tadeusz"
              "apellidos" => "Fojt"
            ]
            4 => array:2 [
              "nombre" => "Leszek"
              "apellidos" => "K&#281;dzierski"
            ]
            5 => array:2 [
              "nombre" => "Katarzyna"
              "apellidos" => "Antoniak"
            ]
            6 => array:2 [
              "nombre" => "Miros&#322;awa"
              "apellidos" => "Janowska"
            ]
            7 => array:2 [
              "nombre" => "Krzysztof"
              "apellidos" => "Pawlicki"
            ]
            8 => array:2 [
              "nombre" => "Krzysztof"
              "apellidos" => "Ziaja"
            ]
            9 => array:2 [
              "nombre" => "Jan"
              "apellidos" => "Du&#322;awa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054557"
        "doi" => "10.3265/Nefrologia.pre2014.Jul.11953"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054557?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054554?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054554/v0_201502091606/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251414054570"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2014.Jun.12595"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2014;34:611-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5668
      "formatos" => array:3 [
        "EPUB" => 283
        "HTML" => 4677
        "PDF" => 708
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Home care programme for patients with advanced chronic kidney disease&#46; A two-year experience"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "611"
          "paginaFinal" => "616"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Programa de atenci&#243;n domiciliaria a pacientes con enfermedad renal cr&#243;nica avanzada&#46; Experiencia de dos a&#241;os"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "12595_16025_61157_en_t112595.jpg"
              "Alto" => 944
              "Ancho" => 1059
              "Tamanyo" => 134152
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Baseline data at the time of inclusion in the programme"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Jos&#233; L&#46; Teruel, Lourdes Rexach, V&#237;ctor Burguera, Antonio Gomis, Nuria Rodr&#237;guez-Mendiola, Alicia D&#237;az, Sergio Collazo, Carlos Quereda"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "Jos&#233; L&#46;"
              "apellidos" => "Teruel"
            ]
            1 => array:2 [
              "nombre" => "Lourdes"
              "apellidos" => "Rexach"
            ]
            2 => array:2 [
              "nombre" => "V&#237;ctor"
              "apellidos" => "Burguera"
            ]
            3 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Gomis"
            ]
            4 => array:2 [
              "nombre" => "Nuria"
              "apellidos" => "Rodr&#237;guez-Mendiola"
            ]
            5 => array:2 [
              "nombre" => "Alicia"
              "apellidos" => "D&#237;az"
            ]
            6 => array:2 [
              "nombre" => "Sergio"
              "apellidos" => "Collazo"
            ]
            7 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Quereda"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699514054573"
        "doi" => "10.3265/Nefrologia.pre2014.Jun.12595"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699514054573?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054570?idApp=UINPBA000064"
    "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054570/v0_201502091605/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Effect of calcium acetate&#47;magnesium carbonate in the treatment of hyperphosphataemia in dialysis patients in real clinical practice&#46; One year follow up"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "617"
        "paginaFinal" => "627"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "&#193;ngel L&#46;M&#46; de Francisco, Lara Belmar, Celestino Pi&#241;era, Mar&#237;a Kislikova, Miguel Seras, Mara Serrano, Zoila Albines, Cristina Sango, Manuel Arias"
        "autores" => array:9 [
          0 => array:4 [
            "nombre" => "&#193;ngel L&#46;M&#46;"
            "apellidos" => "de Francisco"
            "email" => array:1 [
              0 => "angelmartindefrancisco&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Lara"
            "apellidos" => "Belmar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Celestino"
            "apellidos" => "Pi&#241;era"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mar&#237;a"
            "apellidos" => "Kislikova"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Miguel"
            "apellidos" => "Seras"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Mara"
            "apellidos" => "Serrano"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Zoila"
            "apellidos" => "Albines"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Cristina"
            "apellidos" => "Sango"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Manuel"
            "apellidos" => "Arias"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria,  "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Efectos del acetato c&#225;lcico&#47;carbonato magn&#233;sico en el tratamiento de la hiperfosfatemia en pacientes en di&#225;lisis en la pr&#225;ctica cl&#237;nica real&#46; Seguimiento durante un a&#241;o"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60456_en_12527_t1.jpg"
            "Alto" => 472
            "Ancho" => 702
            "Tamanyo" => 235395
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patients and baseline characteristics"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">A number of US<span class="elsevierStyleSup">1</span> and European<span class="elsevierStyleSup">2</span> observational studies reported an increased mortality risk with hyperphosphataemia in dialysis patients&#46; Dietary restriction of phosphate and dialysis are usually not sufficient to control hyperphosphataemia&#46; Consequently&#44; oral phosphate binders are administered in the majority of dialysis patients&#46;</p><p class="elsevierStylePara">The ideal phosphate binder would avidly bind dietary phosphate&#44; have minimal systemic absorption&#44; few side effects&#44; a low pill burden and be inexpensive&#46; Calculations based on the doses usually applied indicated that the cost of treatment with sevelamer- or lanthanum-based agents is substantially higher than the cost of calcium- or magnesium-based binders&#46; Based on total sales figures&#44; annual costs of sevelamer or lanthanum exceeded those of calcium- or magnesium-based binders by four to eight times or more&#44; depending on the dose&#46;<span class="elsevierStyleSup">3</span></p><p class="elsevierStylePara">Calcium acetate&#47;magnesium carbonate &#40;CaMg&#41; is a combination phosphate binder&#46; Both components&#44; administered separately or together&#44; are already well-established phosphate-lowering agents&#46;<span class="elsevierStyleSup">4-14</span> As high doses of phosphate binders are often required to achieve sufficient phosphate reduction&#44; the risk of hypercalcaemia must be considered when using a pure calcium salt as a phosphate binder&#46; In calcium-magnesium combined preparations the proportion of calcium is reduced compared to drugs containing calcium salts only&#44; thus limiting the risk of hypercalcaemia and of a continuously positive calcium balance&#46;<span class="elsevierStyleSup">15</span> A controlled randomised trial investigated the effect of CaMg on serum phosphorus levels compared with sevelamer hydrochloride &#40;HCl&#41;&#46; CaMg was non-inferior to the comparator in controlling serum phosphorus levels at Week 25&#46; There was no change in ionised calcium&#59; there was minimal increase in total serum calcium and a small increase in serum magnesium&#46; CaMg had a good tolerability profile and thus may represent an effective treatment of hyperphosphataemia&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">However&#44; controlled clinical trials do not reflect the real world of clinical practice&#46; The use of less stringent inclusion&#47;exclusion criteria in observational studies allows a closer reflection of the overall patient population than in randomised clinical trials&#46;<span class="elsevierStyleSup">17</span> There is currently little information available on CaMg in real-life clinical practice&#46; The aim of this study was to investigate the use and effectiveness of CaMg in real-world clinical practice in patients on dialysis with hyperphosphataemia&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">SUBJECTS AND METHODS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study population</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Patients aged &#8805;18 years with chronic kidney disease &#40;CKD&#41; stage 5 on haemodialysis &#40;HD&#41; or peritoneal dialysis &#40;PD&#41; who had been prescribed CaMg to control serum phosphorus participated in this study&#46; The study was conducted in conformity with International Conference on Harmonisation - Good Clinical Practice &#40;ICH-GCP&#41; and the Declaration of Helsinki&#46; All patients provided their written informed consent prior to entering the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study design and procedure</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">This open-label&#44; prospective non-interventional observational study enrolled patients from a single centre &#40;Servicio de Nefrolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#44; Universidad de Cantabria&#44; Santander&#44; Spain&#41; between July 2010 and November 2013&#46; The treating physician exclusively determined initiation&#44; dose and duration of CaMg treatment based on recommendations outlined in department protocols&#46; Accordingly&#44; patients on phosphate binder treatment with inadequate phosphorus control or high pill burden or treatment-na&#239;ve patients with P &#62;5&#46;5mg&#47;dL &#40;1&#46;8mmol&#47;L&#41;&#44; Ca &#60;10&#46;4mg&#47;dL &#40;2&#46;6mmol&#47;L&#41;&#44; Mg &#60;3&#46;4mg&#47;dL &#40;1&#46;4mmol&#47;L&#41;&#44; parathyroid hormone &#40;PTH&#41; &#62;150pg&#47;mL &#40;16&#46;5pmol&#47;L&#41; and Kt&#47;V &#8805;1&#46;3 received CaMg &#40;calcium acetate 435mg containing 110mg elemental calcium combined with magnesium carbonate 235mg containing 60mg elemental magnesium &#91;OsvaRen<span class="elsevierStyleSup">&#174;</span>&#93;&#41; at doses determined by the treating physician&#46; Patients received an initial dose prescribed by physicians related to serum phosphorus levels but in general 3-4 pills&#47;day&#46; Dose increase or decrease was based on serum phosphorus levels&#46; Co-medication was maintained according to patient requirements&#46; No clinic visits were required other than those regularly scheduled&#46; No laboratory or diagnostic tests were performed other than those associated with usual patient care&#46; Routine biochemical parameters were measured using standard methods&#46; Measurement of intact PTH was performed using the Scantibodies Total Intact PTH &#40;Abraham Way&#44; Santee&#44; CA 92071&#41;&#46;</p><p class="elsevierStylePara">Besides patient demographics PTH&#44; serum phosphorus&#44; calcium&#44; magnesium and albumin concentration was obtained at baseline and after 3&#44; 6 and 12 months of CaMg treatment respectively&#46; CaMg dosage&#44; concurrent phosphate binder usage&#44; vitamin D and cinacalcet usage were documented throughout the study&#46; Tolerability was assessed by means of adverse event profile and safety laboratory parameters at each study visit&#46;</p><p class="elsevierStylePara">The primary endpoint of this study was efficacy of CaMg in real clinical practice&#44; measured as change in serum phosphorus over one year&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analysis</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara">All data analyses were carried out according to a pre-established analysis plan&#46; The collected data were analysed with epidemiological methods&#44; using the SPSS for Windows programme package &#40;Version 15&#46;0&#44; Chicago&#44; IL&#41;&#46; For continuous variables&#44; statistic parameters including arithmetic mean&#44; standard deviation and range were calculated&#46; Frequency distributions for discrete variables were provided as percentage in relation to the total sample&#46; Evaluation of parameters measuring the clinical course was performed by intraindividual difference analysis using the Student&#8217;s t-test&#46; Differences were calculated per patient and subsequently averaged&#46; For normality and homogeneity of data&#44; Kolgomorov-Smirnow and Levene tests were used&#46; For comparison between groups&#44; the T-Test and Mann-Whitney U test was applied&#46; Missing data were not imputed&#46; All tests were two-sided&#44; and significance was declared at the 0&#46;05 level&#46; Corrected calcium &#40;mg&#47;dL&#41; was calculated as total calcium &#40;mg&#47;dL&#41; &#43; 0&#46;8 &#91;4&#46;0 &#8211; albumin &#40;g&#47;dL&#41;&#93;&#46; For analysis&#44; patients were divided post-hoc into 2 subgroups&#46; Group A comprised patients receiving CaMg alone&#44; group B comprised patients receiving CaMg in addition to one or more other phosphate binders&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patients and baseline characteristics</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In total&#44; 120 patients participated in the study&#46; At database lock&#44; one-year data were available from 67 patients &#40;Figure 1&#41;&#46; Patient demographics&#44; magnesium concentration in dialysis fluids&#44; and baseline laboratory values at initiation of CaMg therapy are shown in Table 1&#46; Ninety-five patients received haemodialysis &#40;61 conventional haemodialysis and 34 on-line hemodiafiltration&#41;&#44; 25 patients were on peritoneal dialysis&#46; Magnesium concentration in the dialysis fluid was 0&#46;5mmol&#47;L &#40;1&#46;2mg&#47;dL&#41; with the exception of 5 PD patients for whom a dialysis solution containing 0&#46;25mmol&#47;L &#40;0&#46;6mg&#47;dL&#41; &#40;Baxter<span class="elsevierStyleSup">&#174;</span>&#41; was used&#46; 79 out of 120 patients received CaMg alone and 41 patients CaMg plus concurrent phosphate binder&#46; In addition to phosphate binding agents&#44; patients received calcitriol&#44; paricalcitol and calcimimetics &#40;Table 2&#41;&#46; At baseline&#44; calcium carbonate and lanthanum carbonate were administered most frequently &#40;23&#37; and 28&#37;&#44; respectively&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Phosphate binder dosage</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Once CaMg was introduced&#44; phosphate binders remained either unchanged&#44; or were reduced or stopped during the observation period&#46; No dose increases were observed during the course of the study&#44; nor were new phosphate binding agents initiated&#46; Before introducing CaMg&#44; there was no washout period considered in clinical practice&#46; At the end of month 12&#44; mean &#40;&#177;SD&#41; pill number of CaMg was 4&#46;75&#177;1&#46;50&#46; In the group CaMg alone &#40;n&#58;41&#41;&#44; at the end of the month 12&#44; mean &#40;&#177;SD&#41; pill number of CaMg was 4&#46;48&#177;1&#46;66&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleBold">Evolution of serum phosphorus levels over time</span></span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Significant reductions in serum phosphorus were achieved in both treatment groups &#40;Figure 2&#41;&#46; No differences were observed between the groups as to the degree of phosphate decrease&#46; Serum phosphorus levels were similar between the groups at all time-points&#46; At baseline&#44; the majority of patients had serum phosphorus levels above the Kidney Disease Improving Global Outcome &#40;KDIGO&#41; and Kidney Disease Outcomes Quality Initiative &#40;K&#47;DOQI&#41; recommended target of 4&#46;5mg&#47;dL &#40;1&#46;4mmol&#47;L&#41; and 5&#46;5mg&#47;dL &#40;1&#46;8mmol&#47;L&#41; respectively&#46; During the course of the study the number of patients with phosphorus levels within the target range increased in both groups &#40;Figure 3&#41;&#46; The highest number of patients within the K&#47;DOQI target range was achieved at 6 months with 78&#37; of patients combined from both groups and at one year with 75&#37;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolucition of calcium over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">After initiation of CaMg&#44; corrected calcium increased in both groups similarly &#40;Figure 4&#41;&#46; In the group receiving CaMg alone&#44; increases were significant compared to baseline at all time-points&#44; whereby in the group receiving CaMg in combination with other phosphate binders&#44; the differences versus baseline reached statistical significance at month 6&#46; Only three out of 120 patients had transient Ca levels mildly above the upper limit of normal &#40;&#62;10&#46;4mg&#47;dL&#44; &#62;2&#46;6mmol&#47;L&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolucition of magnesium over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In patients receiving CaMg alone&#44; magnesium levels increased significantly from 2&#46;44&#177;0&#46;45mg&#47;dL &#40;1&#46;00&#177;0&#46;19mmol&#47;L&#41; at baseline to 2&#46;75&#177;0&#46;44mg&#47;dL &#40;1&#46;13&#177;0&#46;18mmol&#47;L&#41; at the end of one year treatment &#40;p&#60;0&#46;001&#41;&#46; No significant increases were observed in the group receiving combination treatment &#40;Figure 5&#41;&#46; In this group&#44; baseline levels were significantly higher compared to the monotherapeutic group &#40;2&#46;61&#177;0&#46;44mg&#47;dL vs&#46; 2&#46;35&#177;0&#46;43mg&#47;dL &#47; 1&#46;07&#177;0&#46;18mmol&#47;L vs&#46; 0&#46;97&#177;0&#46;18mmol&#47;L&#41;&#46; Magnesium levels were similar in both groups during months 3 to 12&#46; A total of 80 patients &#40;67&#37;&#41; experienced episodes of mild hypermagnesaemia &#40;&#62;2&#46;6mg&#47;mL&#44; 1&#46;05mmol&#47;L&#41; during CaMg treatment&#46; No cases of moderate hypermagnesaemia &#40;4&#46;8-8&#46;6mg&#47;dL&#44; 2&#46;0-3&#46;6mmol&#47;L&#41; were observed&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolution of PTH over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">PTH decreased in both groups over time &#40;Figure 6&#41;&#44; whereby PTH levels were generally lower at all time-points in the group receiving monotherapy&#46; Here&#44; decreases from baseline were significant at all time-points&#46; In the group receiving CaMg in addition to other phosphate binders&#44; the decrease was less pronounced&#44; reaching significance only at month 6&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Evolution of albumin over time</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Albumin levels increased slightly throughout the study &#40;Figure 7&#41;&#46; In monotherapy group the increase from baseline was statistically significant only in month 6&#46; From month 3 on&#44; albumin levels were significantly higher in the group receiving CaMg in addition to another phosphate binder&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Safety</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">In total&#44; 53 patients &#40;44&#46;2&#37;&#41; discontinued CaMg due to transplantation &#40;34&#37;&#41;&#44; exitus &#40;11&#46;3&#37;&#41;&#44; Transfer to another hospital &#40;1&#46;9&#37;&#41;&#44; treatment completion &#40;50&#46;9&#37;&#41; and no analytical data &#40;1&#46;9&#37;&#41;&#46; No treatment-related serious adverse events were reported during the course of the study&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The present observational study explored the effect of CaMg on serum phosphorus levels over one year in dialysis patients under real practice conditions&#46; CaMg treatment resulted in statistically significant reductions in serum phosphorus without affecting the control of related laboratory parameters such as magnesium&#44; calcium&#44; PTH and albumin&#46; This effectiveness of CaMg in clinical practice is consistent with results observed in a randomised controlled clinical trial&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">The publication of K&#47;DOQI clinical guidelines for Bone Metabolism and Disease in 2003<span class="elsevierStyleSup">18</span> promoted significant progress in the issues related to mineral metabolism in CKD&#46; Motivated by the growing evidence regarding the association of mineral metabolism disturbances and cardiovascular disease in CKD&#44; the KDIGO workgroup recommended new targets for mineral metabolism related biochemical parameters&#46;<span class="elsevierStyleSup">19</span> However&#44; several observational studies have concluded that compliance with mineral metabolism targets in dialysis patients was poor&#46; Al Aly et al&#46; reported that CKD-MBD biochemical markers in the majority of dialysis patients fell outside K&#47;DOQI targets&#44; with only 40&#37; having serum phosphorus within the recommended ranges&#46;<span class="elsevierStyleSup">20</span> We have also previously shown in 1&#44;312 patients undergoing haemodialysis at six Spanish centers that the prevalence of patients outside of K&#47;DOQI targets for phosphorus was 46&#37;&#46;<span class="elsevierStyleSup">21</span> Serum phosphate levels are not controlled in &#62;50&#37; of HD patients&#44; mainly because the effectiveness of any phosphate binder therapy is compromised by poor adherence due to high pill burden&#46; At the end of one year of CaMg treatment&#44; the mean number of tablets required to achieve phosphorus control was 4&#46;75&#177;1&#46;50&#44; which is lower than the number of CaMg tablets administered in the CALMAG study &#40;7&#46;3&#177;3&#46;03 tablets per day&#41;&#46;<span class="elsevierStyleSup">16</span> Higher numbers of tablets have been reported in other studies using calcium salts&#46;<span class="elsevierStyleSup">5&#44;6&#44;8</span> This reduction of pill burden might translate into better compliance which&#44; in turn&#44; leads to improved outcomes&#46; Accordingly&#44; in the present study&#44; 78&#37; of patients achieved the K&#47;DOQI target range for serum phosphorus at the end of 6 months treatment with CaMg&#46;</p><p class="elsevierStylePara">Phosphate binders have been used for many years&#44; but the ideal binder in terms of efficacy&#44; patient adherence&#44; safety and costs has yet to be found&#46; Phosphate binders containing aluminium or calcium have well-known drawbacks&#44; such as aluminium toxicity or increased calcium load causing hypercalcaemia which has been associated with vascular calcification&#46; Newer agents such as sevelamer- and lanthanum-based binders avoid calcium burden but are very expensive&#46; Magnesium-containing phosphate binders offer a chance to circumvent some of the problems associated with other agents&#46; In spite of good experience with the use of magnesium-based phosphate binders and excellent results&#44;<span class="elsevierStyleSup">9-14</span> the impact of magnesium in CKD patients still remains unclear in clinical routine practice&#46; The CALMAG study compared safety parameters of CaMg to sevelamer hydrochloride&#46;<span class="elsevierStyleSup">16</span> Both regimens were equally well tolerated with a similar number of adverse events&#46;</p><p class="elsevierStylePara">In our study we observed mild increases in serum magnesium from baseline at the end of one year treatment&#44; but no symptomatic hypermagnesaemia was observed&#46; Although a small increase in serum magnesium occurred in the CaMg group in the CALMAG study&#44; the mean concentration was consistently well below potential symptomatic levels &#40;&#60;4&#46;8mg&#47;dL &#47; 2&#46;0mmol&#47;L&#41;&#46; In fact&#44; this minor increase in serum magnesium may have beneficial effects&#46; Various epidemiological studies demonstrated associations between low serum magnesium levels and an increased risk for metabolic syndrome&#44; type 2 diabetes mellitus &#40;T2DM&#41;&#44; hypertension and atherosclerosis&#46;<span class="elsevierStyleSup">22</span> However&#44; the use of magnesium as a therapeutic agent is only indicated for pre-eclampsia and specific forms of arrhythmias&#46; In a recent study by Khan et al&#46; evaluating 3&#44;530 participants&#44; multivariable-adjusted models indicated that individuals in the lowest quartile of serum magnesium were ~50&#37; more likely to develop atrial fibrillation&#46;<span class="elsevierStyleSup">23</span> In this context&#44; it is important to consider data from a recent meta-analysis reporting an 11&#46;6&#37; prevalence of atrial fibrillation in dialysis patients&#46; The overall incidence of 2&#46;7&#47;100 patient-years was higher than in the general population and has been associated with an increased risk of stroke and mortality&#46;<span class="elsevierStyleSup">24</span> Moreover&#44; magnesium supplementation and mild hypermagnesaemia might have beneficial effects in CKD patients with regards to calcification and mortality&#46;<span class="elsevierStyleSup">25</span> There is concern that increased serum magnesium levels may affect bone in dialysis patients dependent as well as independent of its PTH-lowering effect&#46;<span class="elsevierStyleSup">26</span> In this context&#44; we need more information about the bone effects of magnesium but preliminary data obtained from the CALMAG study shows that CaMg and sevelamer-HCl lower serum levels of iFGF-23 to a similar extent&#46; Changes in bone parameters were dependent on characteristics of the respective phosphate binder&#59; in contrast to sevelamer-HCl&#44; CaMg had no impact on bone turnover markers&#46; In fact the bone turnover parameters alkaline phosphatase&#44; bone AP&#44; procollagen type 1 amino-terminal propeptide 1 osteoprotegerin&#44; beta-crosslaps and tartrate-resistant acid phosphatase 5b increased significantly in the sevelamer-HCl group and they remained almost unchanged in the CaMg group&#44; after the initial phase of P lowering&#46;<span class="elsevierStyleSup">27</span> Further studies would be needed that could give us information about the long-term effects of elevated levels of serum magnesium in patients on dialysis&#46;</p><p class="elsevierStylePara">In our study&#44; a dialysis magnesium concentration of 1&#46;2mg&#47;dL &#40;0&#46;5mmol&#47;L&#41; was used in more than 95&#37; of patients&#46; In dialysis patients&#44; magnesium concentrations are dependent mainly on dialysate magnesium&#46; Magnesium crosses the dialysis and peritoneal membrane readily&#46; Investigation of various magnesium dialysate concentrations in patients undergoing haemodialysis or peritoneal dialysis showed that concentrations of 1&#46;8mg&#47;dL &#40;0&#46;75mmol&#47;L&#41; may cause mild hypermagnesaemia&#44; whereas a concentration of 0&#46;6mg&#47;dL &#40;0&#46;25mmol&#47;L&#41; often leads to hypomagnesaemia&#46; Results for the magnesium dialysate concentration of 1&#46;2mg&#47;dL &#40;0&#46;5mmol&#47;L&#41; are less consistent but magnesium levels were within the normal range in the majority of cases&#46;<span class="elsevierStyleSup">28</span> The inconsistent results of several studies suggest that other factors&#44; such as nutrition and magnesium supplements &#40;e&#46;g&#46; antacids&#41;&#44; may also play an important role in determining serum magnesium levels in dialysis patients&#46;</p><p class="elsevierStylePara">Finally&#44; magnesium containing phosphate binders are relatively inexpensive compared to sevelamer- or lanthanum-based agents&#46; Calculated costs for the treatment with CaMg were about 80&#37; lower compared to sevelamer hydrochloride&#46;<span class="elsevierStyleSup">16&#44;29</span> Nephrologists raised some concerns about the costs of introducing magnesium monitoring&#46; That&#44; however&#44; would be offset by the lower cost of magnesium-containing phosphate binders over sevelamer or lanthanum&#46; Furthermore&#44; most modern multi-channel biochemistry analysers include the measurement of magnesium&#44; if required&#44; without major cost implications&#46;<span class="elsevierStyleSup">30</span></p><p class="elsevierStylePara">A recent metanalisis included all randomised and non-randomised trials that compared outcomes between patients with chronic kidney disease taking calcium-based phosphate binders &#40;with those taking non-calcium-based binders&#46; The final interpretation is that non-calcium-based phosphate binders are associated with a decreased risk of all-cause mortality compared with calcium-based phosphate binders in patients with chronic kidney disease&#46;<span class="elsevierStyleSup">31</span> In our opinion further studies are needed comparing Ca-Mg binders &#40;with low amount of calcium and magnesium effect&#41; with non calcium binders</p><p class="elsevierStylePara">Potential limitations of this study are possible bias introduced by the real world of clinical practice&#46; Physicians prescribe drugs based on their own decisions and the study does not include a washout period before starting CaMg treatment as in controlled clinical trials&#46; The results from this study would have been strengthened if an active comparator or placebo arm had been included&#46; But the present study was designed to assess whether results obtained from clinical trials of CaMg could be replicated in the clinical practice setting&#46; Additional limitations include that dietary data were not collected in this study&#44; primarily for the purpose of ensuring consistency of dietary phosphate intake&#46; We did not precisely record tolerability&#44; but efficacy and tolerability of CaMg have been well documented in previous studies&#46;<span class="elsevierStyleSup">16</span></p><p class="elsevierStylePara">In order to determine the effect of co-medication on phosphorus control by CaMg&#44; conduction of a multivariable analysis was intended&#46; However&#44; this approach was not feasible due to the non-interventional nature of this study&#46; Subgroups with distinct allocation of calcium-containing and calcium-free phosphate binders were too small to yield significant results&#46; Controlled&#44; randomised clinical trials are required to explore the impact of co-medication on phosphorus control&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSIONS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Magnesium-containing phosphate binders have certain intrinsic advantages&#44; since their use avoids aluminium toxicity and allows calcium intake to be reduced or eliminated&#46; The combination of calcium acetate and magnesium carbonate presents a phosphate binder&#44; which is effective and well tolerated in clinical practice&#44; and saves about 80&#37; of treatment costs&#46; Magnesium levels were only slightly elevated and there was minimal increase in total serum calcium&#46; This analysis of current clinical practice shows that &#8211;consistent with findings from a randomised controlled trial&#8211; CaMg treatment provides marked improvement in serum levels of phosphorus helping patients in trying to achieve K&#47;DOQI and KDIGO targets&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Authors declare potential Conflicts of Interest&#46;</p><p class="elsevierStylePara">Honorarios por ponencias&#58; Amgen&#44; Fresenius&#44; Genzyme and Shire&#46;</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60456&#95;en&#95;12527&#95;t1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60456_en_12527_t1.jpg" alt="Patients and baseline characteristics"></img></a></p><p class="elsevierStylePara">Table 1&#46; Patients and baseline characteristics</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60457&#95;en&#95;12527&#95;t2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60457_en_12527_t2.jpg" alt="Concomitant medication at baseline"></img></a></p><p class="elsevierStylePara">Table 2&#46; Concomitant medication at baseline</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60458&#95;en&#95;12527&#95;f1&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60458_en_12527_f1.jpg" alt="Diagram describing the patient flow"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Diagram describing the patient flow</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60459&#95;en&#95;12527&#95;f2&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60459_en_12527_f2.jpg" alt="Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD"></img></a></p><p class="elsevierStylePara">Figure 2&#46; Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60460&#95;en&#95;12527&#95;f3&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60460_en_12527_f3.jpg" alt="Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time"></img></a></p><p class="elsevierStylePara">Figure 3&#46; Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60461&#95;en&#95;12527&#95;f4&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60461_en_12527_f4.jpg" alt="Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 4&#46; Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD </p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60462&#95;en&#95;12527&#95;f5&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60462_en_12527_f5.jpg" alt="Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD"></img></a></p><p class="elsevierStylePara">Figure 5&#46; Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD</p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60463&#95;en&#95;12527&#95;f6&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60463_en_12527_f6.jpg" alt="Evolution of PTH over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 6&#46; Evolution of PTH over time&#46; Data are presented as means&#177;SD </p><p class="elsevierStylePara"><a href="grande&#47;12527&#95;19904&#95;60464&#95;en&#95;12527&#95;f7&#46;jpg" class="elsevierStyleCrossRefs"><img src="12527_19904_60464_en_12527_f7.jpg" alt="Evolution of albumin over time&#46; Data are presented as means&#177;SD "></img></a></p><p class="elsevierStylePara">Figure 7&#46; Evolution of albumin over time&#46; Data are presented as means&#177;SD </p>"
    "pdfFichero" => "P1-E574-S4691-A12527-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437447"
          "palabras" => array:1 [
            0 => "Acetato c&#225;lcico&#47;carbonato magn&#233;sico"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437449"
          "palabras" => array:1 [
            0 => "Hiperfosfatemia"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437451"
          "palabras" => array:1 [
            0 => "Di&#225;lisis"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437453"
          "palabras" => array:1 [
            0 => "Quelante de f&#243;sforo"
          ]
        ]
      ]
      "en" => array:4 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437448"
          "palabras" => array:1 [
            0 => "Calcium acetate&#47;magnesium carbonate"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437450"
          "palabras" => array:1 [
            0 => "Hyperphosphataemia"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437452"
          "palabras" => array:1 [
            0 => "Dialysis"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437454"
          "palabras" => array:1 [
            0 => "Phosphate binder"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Antecedentes&#58;</span> Este estudio observacional se llev&#243; a cabo para investigar el uso y la efectividad&#44; en la pr&#225;ctica cl&#237;nica real&#44; del acetato c&#225;lcico&#47;carbonato magn&#233;sico &#40;CaMg&#41; en el tratamiento de la hiperfosfatemia en pacientes en di&#225;lisis&#46;<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">M&#233;todos&#58;</span> Se realiz&#243; un seguimiento durante 3-12&#160;meses en 120&#160;pacientes adultos con enfermedad cr&#243;nica renal en tratamiento con di&#225;lisis que recib&#237;an monotratamiento con CaMg o en combinaci&#243;n con otros quelantes del f&#243;sforo&#46; Se midieron en suero los valores de f&#243;sforo&#44; calcio&#44; magnesio&#44; hormona paratiroidea y concentraci&#243;n de alb&#250;mina a nivel basal y tras 3&#44; 6 y 12&#160;meses&#44; respectivamente&#46; Adem&#225;s&#44; se document&#243; la dosis de CaMg&#44; el uso de quelantes de f&#243;sforo concomitantes&#44; la vitamina D y el cinacalcet&#46; Los pacientes se dividieron en 2&#160;subgrupos&#58; aquellos a los que solo se les administraba CaMg &#40;n&#61;79&#41; frente a los que recib&#237;an CaMg y un quelante de f&#243;sforo concomitante &#40;n&#61;41&#41;&#46; <span class="elsevierStyleBold">Resultados&#58;</span> En ambos subgrupos&#44; los niveles de f&#243;sforo s&#233;rico disminuyeron de forma significativa&#44; con respecto a los basales&#44; a los 3&#44; 6 y 12 meses de tratamiento con CaMg&#46; El porcentaje de logro de los niveles recomendados de f&#243;sforo s&#233;rico mejor&#243; tras iniciar el tratamiento con CaMg&#46; El mes&#160;6&#44; un total del 78&#37; se encontraba dentro de las recomendaciones objetivo de Calidad de los Resultados de la Insuficiencia Renal &#40;K&#47;DOQI&#41;&#46; El calcio s&#233;rico total corregido aument&#243; durante el tratamiento con CaMg&#44; pero superaba levemente los l&#237;mites superiores normales solo en tres pacientes&#46; Asimismo&#44; se observaron incrementos significativos del magnesio asintom&#225;ticos &#40;<span class="elsevierStyleItalic">P</span>&#60;0&#44;001&#41; en el grupo de monoterapia a los 3&#44; 6 y 12&#160;meses&#46; Un total de 80&#160;pacientes &#40;67&#37;&#41; sufrieron episodios de hipermagnesemia leve &#40;&#62;2&#44;6&#160;mg&#47;mL&#44; 1&#44;05&#160;mmol&#47;L&#41;&#46;<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">Conclusiones&#58;</span><span class="elsevierStyleBold"> </span>El presente an&#225;lisis de la pr&#225;ctica cl&#237;nica habitual&#44; en consonancia con los datos obtenidos de un ensayo aleatorizado controlado&#44; demuestra que el tratamiento con CaMg mejora de forma considerable los niveles de f&#243;sforo s&#233;rico y ayuda a los pacientes a conseguir los objetivos K&#47;DOQI y KDIGO &#40;mejora de los resultados globales en la enfermedad renal&#41;&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Background&#58; </span>This observational study was conducted to investigate the use and effectiveness of calcium acetate&#47;magnesium carbonate &#40;CaMg&#41; in the treatment of hyperphosphataemia in dialysis patients in real-world clinical practice&#46; <span class="elsevierStyleBold">Methods&#58; </span>120 adult CKD patients on dialysis who received CaMg alone or in combination with other phosphate binders were followed-up for 3-12 months&#46; Serum phosphorus&#44; calcium&#44; magnesium&#44; parathyroid hormone and albumin concentration was measured at baseline and after 3&#44; 6 and 12 months respectively&#46; In addition&#44; CaMg dosage&#44; use of concurrent phosphate binders&#44; vitamin D and cinacalcet was documented&#46; Patients were evaluated in 2 subgroups &#8211; CaMg alone &#40;n&#61;79&#41; vs&#46; CaMg &#43; concurrent phosphate binder &#40;n&#61;41&#41;&#46; <span class="elsevierStyleBold">Results&#58; </span>In both subgroups serum phosphorus levels decreased significantly from baseline at 3&#44; 6 and 12 months of CaMg treatment&#46; The percentage achievement of recommended serum phosphorus targets improved after CaMg initiation&#46; At month 6&#44; a total of 78&#37; were within the Kidney Disease Outcomes Quality Initiative &#40;K&#47;DOQI&#41; target range&#46; Total corrected serum calcium increased during CaMg treatment&#44; but mildly exceeded the upper limit of normal in three patients only&#46; Asymptomatic significant increases in magnesium &#40;p&#60;0&#46;001&#41; were observed in the monotherapy group at 3&#44; 6 and 12 months&#46; A total of 80 patients &#40;67&#37;&#41; experienced episodes of mild hypermagnesaemia &#40;&#62;2&#46;6mg&#47;mL&#44; 1&#46;05mmol&#47;L&#41;&#46;<span class="elsevierStyleBold"> Conclusions&#58; </span>This analysis of current clinical practice shows that &#8211; consistent with findings from a randomised controlled trial &#8211; CaMg treatment leads to marked improvement in serum phosphorus levels&#44; helping patients in trying to achieve K&#47;DOQI and KDIGO &#40;Kidney Disease Improving Global Outcome&#41; targets&#46;</p>"
      ]
    ]
    "multimedia" => array:9 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60456_en_12527_t1.jpg"
            "Alto" => 472
            "Ancho" => 702
            "Tamanyo" => 235395
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Patients and baseline characteristics"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60457_en_12527_t2.jpg"
            "Alto" => 270
            "Ancho" => 420
            "Tamanyo" => 121478
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Concomitant medication at baseline"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60458_en_12527_f1.jpg"
            "Alto" => 637
            "Ancho" => 422
            "Tamanyo" => 217587
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Diagram describing the patient flow"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60459_en_12527_f2.jpg"
            "Alto" => 371
            "Ancho" => 700
            "Tamanyo" => 167556
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of serum phosphorus over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Fig. 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60460_en_12527_f3.jpg"
            "Alto" => 473
            "Ancho" => 700
            "Tamanyo" => 166417
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Percentage achievement of KDOQI and KDIGO recommended serum phosphorus targets over time"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60461_en_12527_f4.jpg"
            "Alto" => 378
            "Ancho" => 698
            "Tamanyo" => 168462
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of corrected calcium over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      6 => array:8 [
        "identificador" => "fig7"
        "etiqueta" => "Fig. 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60462_en_12527_f5.jpg"
            "Alto" => 396
            "Ancho" => 700
            "Tamanyo" => 165645
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of serum magnesium over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      7 => array:8 [
        "identificador" => "fig8"
        "etiqueta" => "Fig. 6"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60463_en_12527_f6.jpg"
            "Alto" => 378
            "Ancho" => 700
            "Tamanyo" => 168646
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of PTH over time&#46; Data are presented as means&#177;SD"
        ]
      ]
      8 => array:8 [
        "identificador" => "fig9"
        "etiqueta" => "Fig. 7"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "12527_19904_60464_en_12527_f7.jpg"
            "Alto" => 380
            "Ancho" => 700
            "Tamanyo" => 160166
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution of albumin over time&#46; Data are presented as means&#177;SD"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:31 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9531176" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-55. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20466670" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362(14):1312-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20375408" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 2006;1:704-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699276" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086935" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Qunibi WY, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18423809" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ring T, Nielsen C, Andersen SP, Behrens JK, Sodemann B, Kornerup HJ. Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis: a controlled study. Nephrol Dial Transplant 1993;8:341-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8390009" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991;6:170-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1866045" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Delmez JA, Tindira CA, Windus DW, Norwood KY, Giles KS, Nighswander TL, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1391713" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996;49:163-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8770963" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr 2007;17:416-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17971314" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial 2007;20:333-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17635824" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009;13:453-59."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008;40:193-201. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18193489" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Deuber HJ. Long-term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. Nieren-und Hochdruckkrankheiten 2004;33:403-8."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20530499" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrol Dial Transplant 2009;24(9):2852-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19369690" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-S202."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int \u{A0}Suppl 2009;(113):S1-S130."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004;24:422-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15308874" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006;21(2):459-65."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Geiger H, Wanner C. Magnesium in disease. Clin Kidney J 2012;5(Suppl 1):i25-i38."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 2013;127(1):33-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23172839" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27(10):3816-22. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23114904" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012;5(Suppl 1):i52-i61."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009;22:37-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19250445" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28(9):2383-92. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23787550" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012;5(Suppl 1):i39-i51."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ Rev 2011;1(1):1. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22828213" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "De Francisco ALM, Rodriguez M. Magnesium ¿ its role in CKD. Nefrologia 2013;33(3):389-99. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23640095" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013;382(9900):1268-77. <a href="http://www.ncbi.nlm.nih.gov/pubmed/23870817" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003400000005/v0_201502091605/X2013251414054562/v0_201502091605/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003400000005/v0_201502091605/X2013251414054562/v0_201502091605/en/P1-E574-S4691-A12527-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251414054562?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 6 3 9
2024 October 87 48 135
2024 September 93 49 142
2024 August 119 61 180
2024 July 81 42 123
2024 June 93 54 147
2024 May 105 41 146
2024 April 90 47 137
2024 March 68 36 104
2024 February 65 29 94
2024 January 70 29 99
2023 December 84 34 118
2023 November 125 38 163
2023 October 111 35 146
2023 September 92 31 123
2023 August 90 23 113
2023 July 95 32 127
2023 June 72 28 100
2023 May 72 42 114
2023 April 67 21 88
2023 March 83 31 114
2023 February 60 17 77
2023 January 62 30 92
2022 December 70 36 106
2022 November 68 34 102
2022 October 59 33 92
2022 September 40 38 78
2022 August 60 48 108
2022 July 49 44 93
2022 June 44 42 86
2022 May 29 39 68
2022 April 53 44 97
2022 March 41 50 91
2022 February 49 46 95
2022 January 54 32 86
2021 December 31 39 70
2021 November 45 40 85
2021 October 81 43 124
2021 September 60 28 88
2021 August 52 35 87
2021 July 57 40 97
2021 June 67 23 90
2021 May 42 31 73
2021 April 99 55 154
2021 March 78 35 113
2021 February 77 19 96
2021 January 48 15 63
2020 December 49 20 69
2020 November 67 16 83
2020 October 51 24 75
2020 September 52 21 73
2020 August 37 10 47
2020 July 67 11 78
2020 June 65 15 80
2020 May 68 12 80
2020 April 88 22 110
2020 March 65 15 80
2020 February 77 15 92
2020 January 113 29 142
2019 December 82 47 129
2019 November 75 25 100
2019 October 90 21 111
2019 September 80 32 112
2019 August 75 49 124
2019 July 67 17 84
2019 June 54 32 86
2019 May 61 15 76
2019 April 115 36 151
2019 March 72 26 98
2019 February 45 16 61
2019 January 59 32 91
2018 December 121 52 173
2018 November 90 17 107
2018 October 90 15 105
2018 September 103 14 117
2018 August 65 15 80
2018 July 74 16 90
2018 June 57 9 66
2018 May 71 13 84
2018 April 75 9 84
2018 March 78 9 87
2018 February 63 14 77
2018 January 57 10 67
2017 December 55 17 72
2017 November 71 16 87
2017 October 58 22 80
2017 September 47 24 71
2017 August 50 15 65
2017 July 54 24 78
2017 June 66 31 97
2017 May 75 20 95
2017 April 56 38 94
2017 March 53 22 75
2017 February 49 18 67
2017 January 43 15 58
2016 December 82 14 96
2016 November 91 16 107
2016 October 183 12 195
2016 September 217 5 222
2016 August 229 13 242
2016 July 225 14 239
2016 June 172 0 172
2016 May 183 0 183
2016 April 161 0 161
2016 March 135 0 135
2016 February 154 0 154
2016 January 153 0 153
2015 December 126 0 126
2015 November 87 0 87
2015 October 115 0 115
2015 September 87 0 87
2015 August 114 0 114
2015 July 100 0 100
2015 June 69 0 69
2015 May 91 0 91
2015 April 11 0 11
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)